skip to content

CATALYST News

Earnings Insight

Earnings Calendar

Date Time Symbol company_name Period Metric Estimate Actual Surprise YrAgo Growth sector_industry
06/04/2026 BMO BF-A Brown Forman Inc Class A Common Stock Q4 2026 EPS 0.32 0.12 -62.50 0.31 -61.30
06/04/2026 BMO BF-A Brown Forman Inc Class A Common Stock Q4 2026 REV 878.40 M 912.00 M 3.83 894.00 M 2.01
06/04/2026 BMO BF-B Brown Forman Inc Class B Common Stock Q4 2026 EPS 0.33 0.12 -63.64 0.31 -61.30
06/04/2026 BMO BF-B Brown Forman Inc Class B Common Stock Q4 2026 REV 883.84 M 912.00 M 3.19 894.00 M 2.01
06/04/2026 BMO CAL Caleres Q1 2026 EPS 0.31 0.38 22.58 0.22 72.70
06/04/2026 BMO CAL Caleres Q1 2026 REV 657.60 M 666.60 M 1.37 614.22 M 8.53
06/04/2026 BMO CIEN Ciena Q2 2026 EPS 1.46 1.64 12.33 0.42 290.50
06/04/2026 BMO CIEN Ciena Q2 2026 REV 1.51 B 1.57 B 4.30 1.13 B 39.45
06/04/2026 BMO CMCO Columbus McKinnon Q4 2026 EPS 0.45 0.24 -46.67 0.60 -60.00
06/04/2026 BMO CMCO Columbus McKinnon Q4 2026 REV 370.16 M 437.83 M 18.28 246.89 M 77.34

Pre-Market Insights

Pre-Market Movers

Date Time Symbol Company Name Last Updated PrevClose Price Change Percent stockprice52wklow stockprice52wkhigh 52Wk Range company_sector company_industry Sector / Industry dailyvolume marketcap news_link Catalyst News
06/04/2026 07:04 PM ICCM IceCure Medical Ltd 04-Jun 09:18 5.17 4.44 4.29 2,860.00 3.75 42.00 $3.75 ~ $42.00 Healthcare Medical Devices 157.73 347.76
06/04/2026 07:05 PM CXAI CXApp Inc. 04-Jun 09:20 0.26 0.30 0.14 87.50 0.13 1.15 $0.13 ~ $1.15 Technology Software - Application 516.06 5.97 CXApp Stock Skyrockets After EngineRoom Acquisition Announcement
Benzinga | 2026-06-04 14:09:03
CXApp (CXAI) Stock Soars After Hours: Why Is It Moving?
Benzinga | 2026-06-04 01:56:45
06/04/2026 07:05 PM FOXX Foxx Development Holdings Inc. 04-Jun 09:20 5.25 4.65 1.64 54.49 1.71 8.88 $1.71 ~ $8.88 Technology Consumer Electronics 73.43 36.97
06/04/2026 07:05 PM HCAT Health Catalyst, Inc. 04-Jun 09:20 1.94 1.79 0.46 34.59 0.96 4.29 $0.96 ~ $4.29 Healthcare Health Information Services 27.63 143.35
06/04/2026 07:05 PM MOBX Mobix Labs, Inc. 04-Jun 09:20 2.21 2.92 0.69 30.94 1.31 14.40 $1.31 ~ $14.40 Technology Semiconductors 45.38 14.60 Mobix Labs Stock Jumps On Planned Acquisition Of American-Built Drone Manufacturer
Benzinga | 2026-06-04 09:00:51
06/04/2026 07:04 PM EDHL Everbright Digital Holding Limited 04-Jun 09:20 4.19 3.47 0.78 29.00 2.00 110.08 $2.00 ~ $110.08 Communication Services Advertising Agencies 60.41 6.98
06/04/2026 07:00 PM FOFO Hang Feng Technology Innovation Co. 04-Jun 09:20 6.18 7.84 1.38 21.36 1.75 68.00 $1.75 ~ $68.00 Industrials Consulting Services 802.13 46.79
06/04/2026 07:05 PM ACCL Acco Group Holdings Limited Ordinar 04-Jun 09:20 1.31 1.79 0.29 19.33 1.23 5.00 $1.23 ~ $5.00 Industrials Consulting Services 14.46 18.27
06/04/2026 03:11 PM MBBC Marathon Bancorp, Inc. 04-Jun 08:53 14.00 16.00 2.17 15.69 9.90 15.75 $9.90 ~ $15.75 Financial Banks - Regional 2.05 41.31
06/04/2026 07:01 PM RUM Rumble Inc. 04-Jun 09:20 8.18 9.50 1.17 14.05 4.62 10.99 $4.62 ~ $10.99 Communication Services Internet Content & Information 13.33 3.55

Bio-Pharm Insight

FDA Calendar

Date Symbol Company time event_type Drug Drug Details Status Catalyst target_date_from target_date_to Catalyst Summary Source
05/19/2026 CGEM Cullinan Therapeutics 07:00 AM FDA Decision CLN-049 CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia Phase 1 Orphan Drug Designation 05/19/2026 05/19/2026 Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia
09/05/2025 CERO CERo Therapeutics Holdings 08:00 AM FDA Decision CER-1236 For the treatment of Acute Myeloid Leukemia (AML) Phase 2 Fast Track Designation 09/05/2025 09/05/2025
09/04/2025 AMRX Amneal Pharmaceuticals 04:01 PM FDA Decision Risperdal Consta An extended-release injectable suspension 12.5 mg/vial, 25 mg/vial, 37.5 mg/vial and 50 mg/vial, Approved FDA Approval 09/04/2025 09/04/2025
09/04/2025 LLY Eli Lilly and Company 07:45 AM FDA Decision Olomorasib + KEYTRUDA (pembrolizumab) For the first-line treatment of patients with unresectable advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation and PD-L1 expression = 50% SUNRAY-01 Phase 3 Breakthrough Therapy designation 09/04/2025 09/04/2025
07/02/2025 TIL Instil Bio 06:00 AM FDA Decision AXN-2510 A PD-L1xVEGF Bispecific Antibody, for the treatment of Relapsed/Refractory Solid Tumors Phase 1 Investigational New Drug (IND) 11/30/-0001 11/30/-0001 Instil Bio, Inc. (TIL) announced that the U.S. Food and Drug Administration has cleared an Investigational New Drug (IND) application for AXN-2510. Instil Bio plans to initiate a phase 1 trial of 2510 as monotherapy for patients with relapsed/refractory solid tumors before the end of 2025. The trial is designed to evaluate the safety of 2510 in patients with solid tumors. It also aims to assess the efficacy of the treatment. Additionally, the study will examine the pharmacokinetics and pharmacodynamics of the drug.
07/02/2025 REGN Regeneron Pharmaceuticals 11:00 AM FDA Decision Lynozyfic™ (linvoseltamab-gcpt) To treat adult patients with relapsed or refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti‑CD38 monoclonal antibody. Approved FDA Accelerated Approval 11/30/-0001 11/30/-0001 Regeneron Pharmaceuticals, Inc. (REGN) announced that the U.S. Food and Drug Administration has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy. These therapies include a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 monoclonal antibody. Lynozyfic was granted accelerated approval based on response rate and durability of response in the LINKER-MM1 trial.
06/30/2025 TAK Takeda 08:00 AM FDA Decision GAMMAGARD LIQUID ERC [immune globulin infusion (human)] Intravenous or Subcutaneous Use in People Aged Two and Older with Primary Immunodeficiency Approved FDA Approval 11/30/-0001 11/30/-0001 Takeda (TAK) announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC immune globulin infusion (human) with less than or equal to 2 µg/mL IgA in a 10% solution. It is the only ready-to-use liquid immunoglobulin therapy with low immunoglobulin A content. The therapy is approved as a replacement treatment for people two years of age and older with primary immunodeficiency.

After Hour Movers

Date Time Symbol Company Name Last Updated Close Price Change Percent Day Range 52Wk Range Sector / Industry dailyvolume marketcap news_link Catalyst News
06/04/2026 07:05 PM BGMS Bio Green Med Solution, Inc. 04-Jun 19:05 1.06 2.64 1.58 149.06 $1.04 ~ $1.08 $0.73 ~ $23.25 5.12 2.32
06/04/2026 07:05 PM RMSG Real Messenger Corporation 04-Jun 19:05 1.12 1.71 0.59 52.68 $0.87 ~ $1.17 $0.33 ~ $5.46 710.68 10.72
06/04/2026 07:05 PM SMTK SmartKem, Inc. 04-Jun 19:05 0.34 0.51 0.17 50.00 $0.28 ~ $0.34 $0.15 ~ $3.80 328.74 1.53
06/04/2026 03:58 PM BSLK Bolt Projects Holdings, Inc. 04-Jun 15:58 0.05 0.07 0.02 40.00 $0.05 ~ $0.05 $0.04 ~ $17.55 1.63 110.00
06/04/2026 07:03 PM BBCP Concrete Pumping Holdings, Inc. 04-Jun 19:03 7.98 9.98 2.00 25.06 $7.77 ~ $8.01 $5.56 ~ $8.13 181.10 403.07 Concrete Pumping Holdings, Inc. (BBCP) Q2 2026 Earnings Call Transcript
Seeking Alpha | 2026-06-04 18:52:57
Concrete Pumping Q2 Earnings Call Highlights
MarketBeat | 2026-06-04 18:06:55
Concrete Pumping (BBCP) Exceeds EPS and Revenue Expectations; FY26 Revenue Outlook Strong
Catalyst picR | 2026-06-04 16:22:12
What's driving Concrete Pumping Holdings ($BBCP) shares jumping post-market?
Catalyst picR | 2026-06-04
06/04/2026 07:05 PM ACCL Acco Group Holdings Limited Ordinar 04-Jun 19:05 1.31 1.58 0.27 20.61 $1.30 ~ $2.16 $1.23 ~ $5.00 14.46 18.27
06/04/2026 07:05 PM DXST Decent Holding Inc. 04-Jun 19:05 3.30 3.94 0.64 19.39 $3.24 ~ $7.20 $1.50 ~ $62.00 2.16 2.14
06/04/2026 07:05 PM CETX Cemtrex, Inc. 04-Jun 19:05 0.55 0.65 0.10 18.18 $0.53 ~ $0.60 $0.51 ~ $22.05 974.03 6.06
06/04/2026 07:05 PM DEVS DevvStream Corp. Common Stock 04-Jun 19:05 0.46 0.54 0.08 17.39 $0.45 ~ $0.60 $0.11 ~ $10.10 11.94 2.02
06/04/2026 07:05 PM HKIT Hitek Global Inc. 04-Jun 19:05 0.35 0.41 0.06 17.14 $0.33 ~ $0.43 $0.33 ~ $627.00 7.14 70.00

After Hour Insights

© Catalyst picR 2025-26